Viking Fund

The Viking Fund completed investing in 2009 and is no longer operating as a fund. The Viking Fund is a co-investment venture capital fund specializing in the start-up, early, expansion, and growth stage investments in limited companies. It does not consider investments in agriculture and fisheries sectors and to rescue failing businesses. It seeks to invest alongside a private sector investor and can invest in the second round of funding. The fund seeks to invest in almost all industrial sectors with focus on information, communications, technology, software, medical technology, renewable energy systems, digital instrumentation, and chemical and pharmaceutical innovation. It invests in the Yorkshire and Humber region. The fund typically invests between £0.05 million ($0.07 million) and £0.399 million ($0.59 million). It typically invests between £0.01 million ($0.02 million) and £0.10 million ($0.20 million) in the first stage of financing. The fund can also make follow on investments up to an aggregate of £0.20 million ($0.40 million) per company. It seeks to invest in funding rounds between £0.02 million ($0.04 million) and £0.25 million ($0.50 million). The fund seeks to invest in the form of equity or loan finance. It seeks to appoint a Non-Executive Director on the Board of the portfolio.

2 past transactions

Diurnal Group

Grant in 2009
Diurnal is an innovative pharmaceutical company that creates high-value therapeutics using advanced proprietary formulations and novel physiological treatment regimes of approved drugs for use in the endocrine (hormone) area. Founded in 2004, Diurnal is headquartered in Cardiff, United Kingdom, and is a specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

Cizzle Biotech Ltd.

Venture Round in 2008
Cizzle Biotech Ltd. focuses on the development of CIZ1 gene and its potential as a diagnostic biomarker for the early detection and management of lung cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.